Evaluation of the intravenous tranexamic acid effect on blood loss and surgical field quality during nasal surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013012911822N3

Enrollment

Registered

2013-03-09

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heamorrhage. Unintentional cut, puncture, perforation or haemorrhage during surgical and medical care During surgical operation

Interventions

Intervention 1: During nasal operation, patients will receive 500 mg intravenous tranexamic acid mixed up in 500ml lactated Ringer's solution with concentration 1mg/ml and maximum infusion rate 100mg/

Treatment - Drugs

During nasal operation, patients will receive 500 mg intravenous tranexamic acid mixed up in 500ml lactated Ringer's solution with concentration 1mg/ml and maximum infusion rate 100mg/min and maximum

During nasal operation, control patients will receive lactated Ringer's solution as maintenance therapy.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Nasal surgery; 18 to 65 years old; ASA = II Exclusion criteria: Patient refuse; Surgery time less than 30 minutes; Renal dysfunction; Impaired color vision; Abnormal coagulation test; History of thrombosis or deep vein thrombosis; Ischemic heart disease and arrhythmia; Central nerve system disorder; Allergy to tranexamic acid; Usage Herbal medications; Pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Volume of blood in suction bottle. Timepoint: At end of surgery. Method of measurement: Viewing chamber volume per ml.;Quality of hemorrhage. Timepoint: each 20 min. Method of measurement: Boezzart criteria.;Hematocrit. Timepoint: Preoperative and six hours postoperative. Method of measurement: Automated Cell Counter.;Hemoglobin. Timepoint: Preoperative and six hours postoperative. Method of measurement: Automated Cell Counter.;Satisfactory of surgeon from bleeding. Timepoint: At end of surgery. Method of measurement: ask the surgeon.	—

Measure

Time frame

Volume of blood in suction bottle. Timepoint: At end of surgery. Method of measurement: Viewing chamber volume per ml.;Quality of hemorrhage. Timepoint: each 20 min. Method of measurement: Boezzart criteria.;Hematocrit. Timepoint: Preoperative and six hours postoperative. Method of measurement: Automated Cell Counter.;Hemoglobin. Timepoint: Preoperative and six hours postoperative. Method of measurement: Automated Cell Counter.;Satisfactory of surgeon from bleeding. Timepoint: At end of surgery. Method of measurement: ask the surgeon.

—

Secondary

Measure	Time frame
Impaired color vision. Timepoint: the day after sugery. Method of measurement: Ask the patient.;Nausea. Timepoint: The day after sugery. Method of measurement: Ask the patient.;Vomiting. Timepoint: The day after sugery. Method of measurement: Ask the patient.;Seizure. Timepoint: The day after sugery. Method of measurement: observation of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Karkhanei

Hamadan University of Medical sciences

karkhanei@umsha.ac.ir+98 81 1838 0574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026